Treatment of bacterial vaginosis in patients with cervical and uterine cancer in the late stages after antitumor treatment. Possibilities of using dequalinium chloride

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background: According to the recommendations of the International Society for the Study of Vulvar and Vaginal Diseases (ISSVD), bacterial vaginosis is considered a condition associated with an imbalance in the vaginal microflora, in which there is a decrease in the number of lactobacilli and the predominance of anaerobic microorganisms. ISSVD specialists emphasize the importance of an approach that combines pathogen eradication and restoration of normal vaginal microbiota. This approach is especially relevant for patients who have undergone chemo- or radiation therapy for cervical and uterine cancer, due to changes in the hormonal profile, vaginal microflora and local immunity, which significantly increases the risk of BV recurrence.

Objective: Analysis of current literature data on the effectiveness of BV treatment with dequalinium chloride (LS Septofemin®) in patients with oncological processes of the cervix and uterine body.

Material and methods: A review of articles available in search databases published over the past decade was performed. Current scientific results on the efficacy of dequalinium chloride (LS Septofemin®) in patients with a history of cervical and uterine cancer are outlined.

Results: This review showed the importance of determining the vaginal microbiota in BV for the selection of effective therapy. Dequalinium chloride (LS Septofemin®) has confirmed its clinical efficacy and drug safety in patients with a history of cancer.

Conclusion: Dequalinium chloride (LS Septofemin®) can be recommended as a therapy for BV, as well as mixed vaginitis in women who have received antitumor treatment and are faced with the problem of vaginal dysbiotic disorders after chemo- or radiation therapy for cervical and uterine cancer.

全文:

受限制的访问

作者简介

Anastasia Bychkova

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov; National Medical Research Radiological Center

编辑信件的主要联系方式.
Email: a_bychkova88@mail.ru
ORCID iD: 0000-0003-4855-8188

Obstetrician-Gynecologist, Oncologist at the Department of Aesthetic Gynecology and Rehabilitation, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov; A.F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological Center

俄罗斯联邦, Moscow; Obninsk

Inna Apolikhina

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: i_apolikhina@oparina4.ru
ORCID iD: 0000-0002-4581-6295

Dr. Sci. (Med.), Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov; Professor, Department of Obstetrics, Gynecology, Perinatology and Reproductology, Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University)

俄罗斯联邦, Moscow; Moscow

Liana Mkrtchyan

National Medical Research Radiological Center

Email: liana6969@mail.ru
ORCID iD: 0000-0002-5027-5331

Dr. Sci. (Med.), Head of the Department of Medical Rehabilitation and Restorative Technologies, A.F. Tsyb Medical Radiological Research Center 

俄罗斯联邦, Obninsk

Liana Tarnaeva

National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov

Email: li.tarnaeva@ya.ru
ORCID iD: 0009-0006-7500-7516

Obstetrician-Gynecologist, Postgraduate Student

俄罗斯联邦, Moscow

参考

  1. Vieira-Baptista P., Stockdale C.K., Sobel J. International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis. 2023. https://doi.org/10.59153/adm.rdtv.001
  2. Swidsinski S., Moll W.M., Swidsinski A. Bacterial vaginosis–vaginal polymicrobial biofilms and dysbiosis. Dtsch Arztebl Int 2023;120:347–54. https://doi.org/10.3238/arztebl.m2023.0090
  3. Raba G., Durkech A., Malík T., et al.; Fluomizin Study Group. Efficacy of Dequalinium Chloride vs Metronidazole for the Treatment of Bacterial Vaginosis: A Randomized Clinical Trial. JAMA Netw Open. 2024 May 1;7(5):e248661. https://doi.org/10.1001/jamanetworkopen.2024.8661
  4. Bradshaw C.S., Plummer E.L., Muzny C.A., et al. Bacterial vaginosis. Nat Rev Dis Primers. 2025 Jun 19;11(1):43. https://doi.org/10.1038/s41572-025-00626-1
  5. van de Wijgert J.H.H.M. The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention. PLoS Med. 2017 Dec 27;14(12):e1002478. doi: 10.1371/journal.pmed.1002478
  6. Peebles K., Velloza J., Balkus J.E., et al. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2019 May;46(5):304–311. https://doi.org/10.1097/OLQ.0000000000000972
  7. Cerca N., Vaneechoutte M., Guschin A., Swidsinski A. Polymicrobial infections and biofilms in women’s health: Gahro Expert Group Meeting Report. Res Microbiol. 2017 Nov-Dec;168(9-10):902–904. https://doi.org/10.1016/j.resmic.2017.07.002
  8. Хашукоева А.З., Маркова Э.А., Дугиева М.З. и др. Алгоритм диагностики и лечения бактериального вагиноза. Акушерство и гинекология. 2021;9(прил.):4–10 [Khashukoeva A.Z., Markova E.A., Dugieva M.Z., Khlynova S.A., Karanashev A.H. Algorithm of diagnosis and treatment of bacterial vaginosis. Obstetrics and gynecology. 2021;9(suppl.):4–10. (In Russ.)].
  9. Coudray M.S., Madhivanan P. Bacterial vaginosis-A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2020 Feb;245:143–148. https://doi.org/10.1016/j.ejogrb.2019.12.035
  10. Bautista C.T., Wurapa E., Sateren W.B. et al. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Military Med Res. 2016;3:4. https://doi.org/10.1186/s40779-016-0074-5
  11. Hay P. Bacterial vaginosis. Medicine. 2014;42(7):359–63.
  12. Bradshaw C.S., Sobel J.D. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis. 2016;214 Suppl 1:S14–20.
  13. Клинические рекомендации. Бактериальный вагиноз. (04.05.2022) 2024. Утверждены Минздравом РФ. [Clinical recommendations. Bacterial vaginosis. (05/04/2022) 2024. Approved by the Ministry of Health of the Russian Federation. URL: http://disuria.ru/_ld/11/1191_kr22N89MZ.pdf (In Russ.)].
  14. Sung H., Ferlay J., Siegel R.L., et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.
  15. Small W.Jr., Bacon M.A., Bajaj A., et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–12.
  16. Chambers L.M., Bussies P., Vargas R., et al. The microbiome and gynecologic cancer: current evidence and future opportunities. Curr Oncol Rep. 2021;23(8):92.
  17. Wahid M., Dar S.A., Jawed A., et al. Microbes in gynecologic cancers: causes or consequences and therapeutic potential. Sem Cancer Biol. 2022;86(Pt 2):1179–89.
  18. Endometrial Cancer Statistics World Cancer Research Fund International WCRF International. [(accessed on 30 April 2022)]. Available online: https://www.wcrf.org/cancer-trends/endometrial-cancer-statistics/
  19. Lu W., He F., Lin Z., et al. Dysbiosis of the Endometrial Microbiota and Its Association with Inflammatory Cytokines in Endometrial Cancer. Int J Cancer. 2021;148:1708–1716. https://doi.org/10.1002/ijc.33428
  20. Белявская В.А., Чердынцева Н.В., Кжышковска Ю.Г., Литвяков Н.В. Микробиом, имунная система и рак: три стороны одной медали. Сибирский онкологический журнал. 2022;21(6):131–144. [Belyavskaya V.A., Cherdyntseva N.V., Kzhyshkovska J.G., Litvyakov N.V. Microbiome, immune system and cancer: three sides of the one medal. Siberian journal of oncology. 2022;21(6):131–144. (In Russ.)].https://doi.org/10.21294/1814-4861-2022-21-6-131-144
  21. Heidar N.A., Bhat T.A., Shabir U., Hussein A.A. The urinary microbiome and bladder cancer. Life (Basel). 2023;13(3):812.
  22. Wu P., Zhang G., Zhao J., et al. Corrigendum: profiling the urinary microbiota in male patients with bladder Cancer in China. Front Cell Infect Microbiol. 2018;8:429.
  23. Schwabe R.F., Jobin C. The Microbiome and Cancer. Nat Rev Cancer. 2013;13:800–812. https://doi.org/10.1038/nrc3610
  24. Sanderson P.A., Critchley H.O.D., Williams A.R.W., et al. New Concepts for an Old Problem: The Diagnosis of Endometrial Hyperplasia. Hum Reprod Update. 2017;23:232–254. https://doi.org/10.1093/humupd/dmw042
  25. Wallace A.E., Gibson D.A., Saunders P.T.K., Jabbour H.N. Inflammatory Events in Endometrial Adenocarcinoma. J Endocrinol. 2010;206:141–157. https://doi.org/10.1677/JOE-10-0072
  26. Bilardi J.E., Walker S., Temple-Smith M., et al. The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS ONE. 2013;8(9):e74378.
  27. Thomas-White K., Navarro P., Wever F., et al. Psychosocial impact of recurrent urogenital infections: a review. Womens Health (Lond). 2023 Jan-Dec;19:17455057231216537. https://doi.org/10.1177/17455057231216537
  28. Muls A., Andreyev J., Lalondrelle S., et al. Systematic Review: The Impact of Cancer Treatment on the Gut and Vaginal Microbiome in Women With a Gynecological Malignancy. Int J Gynecol Cancer. 2017 Sep;27(7):1550–1559. https://doi.org/10.1097/IGC.0000000000000999
  29. Smith S.B., Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017 Jan 15;595(2):451–463. doi: 10.1113/JP271694
  30. Mohammadzadeh F., Dolatian M., Jorjani M., Alavi Majd H. Diagnostic value of Amsel’s clinical criteria for diagnosis of bacterial vaginosis. Glob J Health Sci. 2014;7(3):8–14.
  31. Wang Z. et al. The Diversity of Vaginal Microbiota Predicts Neoadjuvant Chemotherapy Responsiveness in Locally Advanced Cervical Cancer. Microb Ecol. 2022;84(1):302–313. https://doi.org/10.1007/S00248-021-01800-0/FIGURES/10
  32. Wen Q. et al. Associations of the gut, cervical, and vaginal microbiota with cervical cancer: a systematic review and meta-analysis. BMC Women’s Health 2025;25(1):1–13. doi: 10.1186/S12905-025-03599-1
  33. Sherrard J., Donders G., White D. European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge. Int J. STD AIDS. 2011;22:421–429.
  34. Ferris D.G. et al. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. JAMA. 1992;268(1):92–95.
  35. Nyirjesy P., et al. The effects of intravaginal clindamycin and metronidazole therapy on vaginal lactobacilli in patients with BV. Am J Obstetr Gynecol. 2006;194:1277–1282.
  36. Sobel J., Ferris D., Schwebke J. et al. Suppressive antibacterial therapy with 0,75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194:1283–1289.
  37. Workowski K., Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. 2010;59(RR12):1–110. URL: http://www.cdc.gov/mmwr
  38. Sobel J., Ferris D., Schwebke J., et al. Suppressive antibacterial therapy with 0,75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194:1283–1289.
  39. Michael D. Nailor and Jack D. Sobel Tinidazole for bacterial vaginosis. Future Drugs Ltd, 2007.
  40. Livengood C.H., Ferris D.G., Wiesenfeld H.C., et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2007 Aug;110(2 Pt 1):302–9.
  41. Пустотина О.А. Бактериальный вагиноз: патогенез, диагностика, лечение и профилактика. Акушерство и гинекология. 2018;3:150–156. [Pustotina O.A. Bacterial vaginosis: pathogenesis, diagnosis, treatment and prevention. Obstetrics and gynecology. 2018;3:150–156. (In Russ.)].
  42. Ильина И.Ю., Доброхотова Ю.Э. Бактериальный вагиноз. Возможные пути решения проблемы. Русский медицинский журнал. 2020;11:75–78. [Ilina I.Yu., Dobrokhotova Yu.E. Bacterial vaginosis. Possible solutions to the problem. Rus Med J. 2020;11:75–78. (In Russ.)].
  43. Abou Chacra L., Fenollar F., Diop K. Bacterial Vaginosis: What Do We Currently Know? Front Cell Infect Microbiol. 2022 Jan 18;11:672429. https://doi.org/10.3389/fcimb.2021.672429
  44. Slawson D.C. Dequalinium Is Noninferior to Metronidazole for Bacterial Vaginosis. Am Fam Physician. 2024 Nov;110(5):543.
  45. Haydock R., Hepburn T., Ross J., Daniels J., et al. The DEVA trial: protocol for a randomised controlled trial of dequalinium chloride versus usual care antibiotics for the treatment of bacterial vaginosis. Trials. 2022 Dec 21;23(1):1040. doi: 10.1186/s13063-022-06954-x
  46. Eckel F., Farr A., Deinsberger J., et al. Dequalinium Chloride for the Treatment of Vulvovaginal Infections: A Systematic Review and Meta-Analysis. J Low Genit Tract Dis. 2024 Jan 1;28(1):76–83. doi: 10.1097/LGT.0000000000000790 Erratum in: J Low Genit Tract Dis. 2024 Jul 1;28(3):317. https://doi.org/10.1097/LGT.0000000000000823
  47. Mendling W., Weissenbacher E.R., Gerber S., et al. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet. 2016 Mar;293(3):469–84. https://doi.org/10.1007/s00404-015-3914-8
  48. Куценко И.И., Боровиков И.О., Кравцова Е.И. и др. Деквалиния хлорид в терапии вагинальных инфекций. Вопросы гинекологии, акушерства и перинатологии. 2023;22(3):63–78. [Kutsenko I.I., Borovikov I.O., Kravtsova E.I., et al. Dequalinium chloride in the treatment of vaginal infections. Issues of gynecology, obstetrics and perinatology. 2023;22(3):63–78. (In Russ.)]. https://doi.org/10.20953/1726-1678-2023-3-63-78
  49. Mendling W., Brasch J. Guideline vulvovaginal candidosis of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infect immunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012;55(3):1–13. https://doi.org/10.1111/j.1439-0507.2012.02185.x
  50. Antoni Vives J., Cancelo M.J., Losada M.Á., Doménech A. Dequalinium chloride use in adult Spanish women with bacterial vaginosis: an observational study. J Obstet Gynaecol. 2022 Jan;42(1):103–109. https://doi.org/10.1080/01443615.2020.1867966
  51. Carter K.A., Tuddenham S., Brotman R.M. Dequalinium Chloride-An Emerging Option in the Sparse Landscape of Bacterial Vaginosis Therapies. JAMA Netw Open. 2024 May 1;7(5):e248606. https://doi.org/10.1001/jamanetworkopen.2024.8606
  52. Chen Y., Bruning E., Rubino J., Eder S.E. Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage. Womens Health (Lond). 2017 Dec;13(3):58–67.
  53. Аполихина И.А., Тетерина Т.А., Тарнаева Л.А., Бартус К.А.Х. Женское и мужское здоровье сквозь призму рекомендаций Международной федерации гинекологии и акушерства 2023. Новый взгляд на микробиом и интимную гигиену. Акушерство и гинекология. 2023;12:158–66. [Apolikhina I.A., Teterina T.A., Tarnaeva L.A., Bartus AS. Women’s and men’s health through the prism of the recommendations of the International Federation of Gynecology and Obstetrics 2023. A new look at the microbiome and intimate hygiene. Obstetrics and gynecology. 2023;12:158–66. (In Russ.)].
  54. Тетерина Т.А., Аполихина И.А., Чернова Н.И. Интимная гигиена и здоровье женщины. Мать и дитя. 2024;4(42):14–15. [Teterina T.A., Apolikhina I.A., Chernova N.I. Intimate hygiene and women’s health. Mother and child. 2024;4(42):14–15. (In Russ.)].
  55. Аполихина И.А., Тарнаева Л.А. Пробиотики для поддержания экосистемы влагалища. Медицинский совет. 2024;(17):86–90. [Apolikhina IA, Tarnaeva LA. The role of probiotics in maintaining vaginal ecosystem. Meditsinskiy sovet = Medical Council. 2024;(17):86–90. (In Russ.)]. https://doi.org/10.21518/ms2024-489

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025